DIOSynVax

News

An AI-powered universal vaccine tech developed by UK biotech DIOSynVax has shown preliminary efficacy in a world-first human trial.

News

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.